Avitide says a specific SARS-CoV-2 virus spike protein affinity resin greatly helps the current COVID-19 efforts and could greatly accelerate the speed of response in future pandemics. Bioprocess service and consumable firms are looking to support the next wave of COVID-19 vaccines as they progress through the clinic. Last week, we reported that Repligen and Navigo launched an affinity resin specifically for the purification of COVID-19 vaccines. But they are not alone, and New Hampshire-based firm Avitide recently finalized its…

Repligen and Navigo have launched an affinity resin specifically for the purification of COVID-19 vaccines. Last year, bioprocess technology firm Repligen teamed with protein engineering firm Navigo Proteins GmbH to develop an affinity ligand specifically for COVID-19 vaccines. Like many COVID-19 vaccine and therapeutic efforts themselves, the collaboration plus speed of development have borne fruit with the firms launching the NGL COVID-19 Spike Protein Affinity Resin this week. While the handful of COVID-19 vaccines approved so far are not protein-based…

Danaher Corporation reports double-digit sales growth at its bioprocess units Pall and Cytiva, inflated by COVID-related dividends it says will continue this year. For the full year 2020, Danaher Corporation reported net sales of $22.3 billion, a 24.5% increase on the previous year. Life sciences pulled in $10.6 billion of this, up 52% on 2019. While Danaher does not detail its individual business financial figures, the contributions from Cytiva – acquired for $21 billion last April –  and Pall Biotech…